drugset

drugset / Trial / NCT06259981

A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

NCT06259981 ↗

Phase 2 Completed 75 enrolled Glyscend, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.

Timeline

Start: 2024-05-20
Primary completion: 2024-10-23
Completion: 2024-10-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GLY-200	Other / unclassified	2 g	Oral

Indications